These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11485147)

  • 1. Prevention and treatment of veno-occlusive disease.
    Pegram AA; Kennedy LD
    Ann Pharmacother; 2001; 35(7-8):935-42. PubMed ID: 11485147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Veno-occlusive disease after bone marrow transplantation: preventive effect of heparin].
    Parquet N; Devergie A; Socié G; Ribaud P; Espérou H; Gluckman E
    Ann Med Interne (Paris); 1997; 148(2):132-5. PubMed ID: 9238437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
    Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
    Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
    Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of veno-occlusive disease of the liver after bone marrow transplantation: heparin or no heparin?
    Cahn JY; Flesch M; Brion A; Deconinck E; Leconte Des Floris MF; Voillat L; Plouvier E; Amsallem D; Tiberghien P; Fest T
    Blood; 1992 Oct; 80(8):2149-50. PubMed ID: 1391966
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide.
    Jenner MJ; Micallef IN; Rohatiner AZ; Kelsey SM; Newland AC; Cavenagh JD
    Med Oncol; 2000 Nov; 17(4):333-6. PubMed ID: 11114714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.
    Lee JH; Lee KH; Choi JS; Zang DY; Kim SB; Kim SW; Suh C; Lee JS; Kim WK; Lee YS; Kim SH
    J Korean Med Sci; 1996 Apr; 11(2):118-26. PubMed ID: 8835758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation.
    Bearman SI; Hinds MS; Wolford JL; Petersen FB; Nugent DL; Slichter SJ; Shulman HM; McDonald GB
    Bone Marrow Transplant; 1990 Jun; 5(6):407-11. PubMed ID: 2369681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1.
    Higashigawa M; Watanabe M; Nishihara H; Tabata N; Azuma E; Ido M; Ito M; Sakurai M
    Leuk Res; 1995 Jul; 19(7):477-80. PubMed ID: 7637394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Veno-occlusive disease of the liver after bone marrow transplantation. Report of the symposium Autograft in France and the group of study of bone marrow transplantation. France Auto-Greffe et le Groupe d'Etude de la Greffe de Moelle osseuse].
    Rio B; Cahn JY; Attal M; Drouet L; Scrobohaci ML; Degos F; Degott C; Bearman SI; Grañena A; Blaise D
    Presse Med; 1994 Sep 3-10; 23(26):1217-22. PubMed ID: 7831216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low incidence of hepatic veno-occlusive disease in pediatric patients undergoing hematopoietic stem cell transplantation attributed to a combination of intravenous heparin, oral glutamine, and ursodiol at a single transplant institution.
    Lakshminarayanan S; Sahdev I; Goyal M; Vlachos A; Atlas M; Lipton JM
    Pediatr Transplant; 2010 Aug; 14(5):618-21. PubMed ID: 20051023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of tissue plasminogen activator in the treatment of veno-occlusive liver disease after bone marrow transplantation.
    Terra SG; Spitzer TR; Tsunoda SM
    Pharmacotherapy; 1997; 17(5):929-37. PubMed ID: 9324182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation.
    Park SH; Lee MH; Lee H; Kim HS; Kim K; Kim WS; Jung CW; Im YH; Yoon SS; Kang WK; Park K; Park CH; Kim SW
    Bone Marrow Transplant; 2002 Jan; 29(2):137-43. PubMed ID: 11850708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prophylaxis of hepatic veno-occlusive disease by low-molecular-weight heparin and lipo- prostaglandin E1 after allogeneic peripheral blood stem cell transplantation].
    Song CY; Li YH; Guo KY; Wu BY
    Di Yi Jun Yi Da Xue Xue Bao; 2003 May; 23(5):494, 497. PubMed ID: 12754143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Veno-occlusive disease of the liver complicating bone marrow transplantation.
    Baglin TP
    Bone Marrow Transplant; 1994 Jan; 13(1):1-4. PubMed ID: 8019444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of vitamin E and glutamine in the successful treatment of severe veno-occlusive disease following bone marrow transplantation.
    Nattakom TV; Charlton A; Wilmore DW
    Nutr Clin Pract; 1995 Feb; 10(1):16-8. PubMed ID: 7898412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial.
    Attal M; Huguet F; Rubie H; Huynh A; Charlet JP; Payen JL; Voigt JJ; Brousset P; Selves J; Muller C
    Blood; 1992 Jun; 79(11):2834-40. PubMed ID: 1586733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.
    Simon M; Hahn T; Ford LA; Anderson B; Swinnich D; Baer MR; Bambach B; Bernstein SH; Bernstein ZP; Czuczman MS; Slack JL; Wetzler M; Herzig G; Schriber J; McCarthy PL
    Bone Marrow Transplant; 2001 Mar; 27(6):627-33. PubMed ID: 11319593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A trial use of prostaglandin E1 for prevention of hepatic veno-occlusive disease after allogeneic bone marrow transplantation].
    Morio S; Oh H; Kogure K; Ishii H; Ishii A; Nakaseko C; Ikegami T; Kawano E; Matsuura Y; Nishimura M
    Rinsho Ketsueki; 1994 Sep; 35(9):846-52. PubMed ID: 7967053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients.
    Essell JH; Thompson JM; Harman GS; Halvorson RD; Snyder MJ; Callander NS; Clement DJ
    Bone Marrow Transplant; 1992 Oct; 10(4):367-72. PubMed ID: 1422493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.